Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Matt KaeberleinAudio: American English

Can Rapamycin Reverse Alzheimer's? What the Data Actually Shows

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

About this video

Creator description · original textText language: American English

Subscribe to our channel: https://www.youtube.com/@mkaeberlein What if some of the most important drivers of Alzheimer's disease have nothing to do with amyloid plaques—and everything to do with aging biology? In this episode of Longevity Science, I sit down with Dr. Veronica Galvan, Director of the Nathan Shock Center at the University of Oklahoma and Editor-in-Chief of Geroscience, to explore more than a decade of groundbreaking research on mTOR, rapamycin, brain aging, and Alzheimer's disease. Dr. Galvan was among the first researchers to demonstrate that inhibiting mTOR with rapamycin can restore cognitive function, cerebral blood flow, neurovascular coupling, and blood-brain barrier integrity in animal models of Alzheimer's disease and age-related cognitive decline. Even more remarkably, many of these benefits were observed when treatment began after deficits had already developed. We discuss: 🔹 Why aging is the greatest risk factor for Alzheimer's disease 🔹 How mTOR contributes to brain aging and neurodegeneration 🔹 The surprising role of blood vessels in cognitive function 🔹 Rapamycin's effects on cerebral blood flow and the blood-brain barrier 🔹 Evidence for reversal of cognitive deficits in aging mice and rats 🔹 Why nitric oxide signaling may be important—but not sufficient 🔹 Tau pathology, cellular senescence, and inflammation in the aging brain 🔹 Whether senolytics or senomorphics are the better therapeutic strategy 🔹 The mystery of "resilient" individuals who maintain normal cognition despite significant Alzheimer's pathology 🔹 Why large, placebo-controlled human rapamycin trials are urgently needed This conversation dives deep into one of the most promising—and still underexplored—areas of aging biology. If you're interested in Alzheimer's disease, dementia prevention, rapamycin, or the biology of brain aging, this is an episode you won't want to miss. #Longevity #Alzheimers #Rapamycin #BrainHealth #Aging #Dementia #mTOR #Neuroscience #HealthyAging #Geroscience DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find me: Instagram: https://www.instagram.com/mkaeberlein/ LinkedIn: https://www.linkedin.com/in/mkaeberlein/ Twitter: https://twitter.com/mkaeberlein Facebook: https://www.facebook.com/matt.kaeberlein/ --- Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this channel I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!

Matt Kaeberlein · 60 min · Source published: 2026-06-17

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…